IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Recent Advancements in Ocular Drug Delivery Systems: A Comprehensive Review

[1]Monika Nijhawan, [2]Samyuktha Kypa, [3]Nandini kongara, [4]Bhavana Pappala

[1]Asst. Prof, [2]Student, [3]Student, [4]Student

[1]Department of Pharmaceutics,

[1]Gokaraju Rangaraju College of Pharmacy, Hyderabad, India, 500090

Abstract*:* Ocular drug delivery is a critical area of research due to the complexity of the eye's anatomy and the challenges in achieving adequate drug concentrations in ocular tissues. The traditional methods of ocular drug administration, such as eye drops, face several limitations, including poor bioavailability, rapid clearance, and low patient compliance. Recent advancements in ocular drug delivery systems (ODDS) have focused on overcoming these barriers by utilizing novel technologies such as nanoparticles, hydrogels, sustained-release implants, prodrug formulations, gene therapy, and microneedles. This review aims to provide an in-depth analysis of the latest developments in ocular drug delivery systems, focusing on the mechanisms of action, applications, advantages, and challenges associated with these innovations.This article discuss nanoparticle-based systems, hydrogel-based delivery, prodrug strategies, gene therapy, and novel techniques such as microneedles and targeted delivery methods. The future directions of ocular drug delivery systems are also explored, highlighting the need for personalized therapies, improved patient compliance, and multi-functional drug delivery systems. Overall, the ongoing advancements in ODDS have the potential to revolutionize the treatment of ocular diseases, offering better therapeutic outcomes and reduced side effects for patients.

Keywords: Ocular drug delivery systems (ODDS), Nanoparticles, Hydrogels, Sustained-release implants, Gene therapy

1. Introduction:

The human eye is one of the most complex organs in terms of its structure and function. It is continuously exposed to various environmental threats and has evolved several defence mechanisms, making the delivery of therapeutic agents to ocular tissues particularly challenging. Traditional methods of ocular drug delivery, such as topical application through eye drops or systemic administration via oral or injectable routes, have proven inadequate for effectively treating ocular diseases. One of the primary reasons for this limitation is the presence of various anatomical and physiological barriers in the eye that hinder the penetration and bioavailability of drugs. Over the years, a great deal of research has been focused on developing innovative ocular drug delivery systems (ODDS) to overcome these barriers. These systems aim to enhance drug solubility, ensure sustained release, target specific ocular tissues, and reduce the frequency of administration, which is crucial for improving patient compliance, particularly for chronic eye conditions like glaucoma, macular degeneration, and diabetic retinopathy. This review article provides a comprehensive overview of the recent advancements in ocular drug delivery systems. We will explore the challenges that make ocular drug delivery difficult, the various strategies used to overcome these challenges, and the cutting-edge technologies that are currently being investigated for their potential to improve the efficacy and safety of ocular drug delivery.

2. Key Barriers to Ocular Drug Delivery:

Ocular drug delivery faces several challenges that stem from the unique structure and physiology of the eye. These barriers include the anatomical structure of the eye, the protective mechanisms in place, and the pharmacological properties of the drugs themselves.

2.1. Anatomical Barriers

The eye is equipped with several layers of protective tissues that are designed to safeguard it from external threats, but these same protective mechanisms make it difficult for therapeutic drugs to reach the target tissues.

a. Corneal Epithelium: The cornea, which acts as the primary barrier to the eye, is composed of several layers. The epithelial layer, being lipophilic in nature, presents a significant challenge for the delivery of hydrophilic drugs. Lipophilic drugs can permeate more easily, but hydrophilic drugs often require specialized formulations to enhance their permeability across this barrier.

b. Conjunctiva and Sclera: The conjunctiva is a mucous membrane that covers the surface of the eye and contains specialized cells that are part of the immune system. The conjunctiva and sclera provide additional barriers to the delivery of drugs. Any drug that is applied topically to the surface of the eye must pass through these layers to reach deeper ocular tissues, such as the cornea, lens, retina, or vitreous body [(1)].

2.2. Physiological Barriers

In addition to the anatomical barriers, the physiological properties of the eye further complicate ocular drug delivery.

a. Tear Drainage and Lacrimal System: The tear film plays a critical role in protecting the eye from foreign substances by quickly removing them through the lacrimal drainage system. This rapid clearance significantly reduces the residence time of topical drugs on the eye's surface, limiting their bioavailability [(2)].

b. Blood-Ocular Barriers: The blood-aqueous and blood-retinal barriers tightly regulate the entry of systemic drugs into the eye. These barriers are particularly challenging for the treatment of posterior segment diseases, such as diabetic retinopathy and macular degeneration, as drugs must pass through these barriers to reach the retina and vitreous humor [(3)].

2.3. Drug Properties

The inherent physicochemical properties of the drug itself can also impact its ability to penetrate ocular barriers and reach therapeutic concentrations within ocular tissues.

a. Solubility and Permeability: Many drugs intended for ocular use are poorly soluble in water or have low permeability across ocular barriers. This limitation is particularly problematic for hydrophobic drugs, which require specialized delivery vehicles to improve their solubility and bioavailability [(4)].

b. Molecular Size and Charge: The size and charge of a drug molecule play a significant role in determining its ability to penetrate ocular tissues. Larger molecules, such as proteins and peptides, often cannot diffuse easily through the cornea and conjunctiva, making it difficult to deliver them to deeper ocular tissues [(5)].

2.4. Rapid Elimination

Drugs administered topically often undergo rapid elimination through lacrimal drainage into the throat, significantly reducing their bioavailability. Additionally, the high metabolic activity of ocular tissues can lead to the rapid breakdown of drugs before they reach their target site, further limiting their effectiveness [(6)].

2.5. Patient Compliance

Frequent dosing is often required to maintain therapeutic drug concentrations, especially for chronic conditions like glaucoma. This not only burdens patients with an inconvenient treatment regimen but also leads to poor compliance. Invasive treatments, such as intravitreal injections, further deter patients due to the discomfort and risks associated with these procedures [(7)].

2.6. Safety and Toxicity Concerns

Chronic ocular drug delivery, particularly with preservatives found in eye drops (e.g., benzalkonium chloride), can lead to ocular toxicity, dryness, and irritation. Systemic side effects are also a concern, especially when drugs are absorbed into the bloodstream, causing unintended effects such as bradycardia or hypotension [(8)].

3. Recent Developments in Ocular Drug Delivery Systems

Given the numerous challenges in ocular drug delivery, a range of advanced drug delivery systems have been developed to enhance drug penetration, prolong drug release, and improve the targeting of specific ocular tissues. These systems include nanoparticle-based delivery systems, hydrogels, sustained-release implants, prodrug formulations, gene therapy, and microneedle technology [(9)].

3.1. Targeted Delivery Systems

Recent advancements in targeted drug delivery systems, such as nanoparticles and receptor-mediated delivery, have improved the precision of drug delivery within the eye. These systems are designed to target specific cells or tissues, such as the retina, minimizing systemic side effects and improving the efficacy of treatments for conditions like AMD [(21)].

Nanoparticle-based drug delivery systems have become one of the most promising approaches for overcoming the barriers to ocular drug delivery. Nanoparticles are small-sized carriers that can encapsulate drugs and facilitate their transport across ocular barriers.

a. Liposomes: Liposomes are spherical vesicles made of lipid bilayers that can encapsulate both hydrophobic and hydrophilic drugs. Liposomal formulations have been widely investigated for ocular drug delivery due to their ability to improve solubility, stability, and controlled release. Liposomes can penetrate the ocular barriers more effectively and target specific ocular tissues, such as the retina or cornea, thereby improving therapeutic efficacy [(23)].

b. Solid Lipid Nanoparticles (SLNs): SLNs are solid nanoparticles made from lipids and surfactants. They offer several advantages, such as the ability to encapsulate both lipophilic and hydrophilic drugs, controlled release, and enhanced ocular bioavailability. SLNs are also more stable than liposomes, making them suitable for long-term storage and application [(10)].

c. Polymeric Nanoparticles: Polymeric nanoparticles are biodegradable and biocompatible carriers that can release drugs in a controlled manner. These nanoparticles can be designed to release drugs at specific sites within the eye, such as the retina or vitreous humor, making them ideal for treating posterior segment diseases [(11)].



Figure 1: liposome

3.2. Hydrogel-Based Delivery Systems

Hydrogels are three-dimensional networks of hydrophilic polymers that can absorb large amounts of water and release drugs in a controlled manner. These materials have shown significant promise in ocular drug delivery, particularly for the treatment of anterior segment diseases such as dry eye [12].

Smart Hydrogels: Smart hydrogels are designed to respond to environmental stimuli, such as changes in temperature, pH, or ionic strength. These materials can alter their structure and drug-release profile in response to changes in the ocular environment, offering a mechanism for targeted and controlled drug delivery [13].

3.3. Sustained-Release Implants and Inserts

Sustained-release implants and inserts are used to deliver drugs over extended periods, reducing the frequency of administration and improving patient compliance. These devices are typically made from biocompatible materials and can be placed either in the conjunctival sac or inside the eye.

a. Glaucoma Inserts: Several sustained-release implants have been developed to treat glaucoma by releasing anti-glaucoma medications continuously over a prolonged period. These implants offer a significant advantage over topical eye drops, as they reduce the need for frequent application and provide more consistent drug delivery [14].

b. Post-Surgical Implants: Intraocular implants are used to deliver drugs following eye surgeries, such as cataract surgery, to reduce inflammation and promote healing. These implants can provide sustained release of anti-inflammatory agents, antibiotics, or corticosteroids, improving the recovery process and reducing the need for postoperative eye drops [15].

c. Ocular inserts: Ocular inserts are another innovative approach to ocular drug delivery. These medical devices are placed in or around the eye to deliver medication, treat specific conditions, or correct vision. Ocular inserts can be classified into two categories: soluble and insoluble [24].

(i) Soluble inserts: Soluble inserts gradually dissolve or degrade within the eye or tear film, releasing their active ingredient in a controlled manner [25].These inserts are commonly used for the sustained release of medication, such as in the treatment of dry eye or glaucoma. For example, Lacrisert is a soluble insert used for dry eye disease, providing moisture and lubrication to the eye [26]. The main advantages of soluble inserts are their non-invasive nature, controlled drug delivery, and enhanced patient comfort.

Figure 2: typical representation of administration of eye drop solution

(ii) Insoluble inserts: Insoluble ocular inserts, made from materials like silicone or hydrogel, do not dissolve and remain in the eye for extended periods [27]. These inserts are used in situations requiring long-term drug delivery, such as for glaucoma treatment or ocular prosthetics. Their advantages include extended use, reduced dosing frequency, and localized therapy, but they may cause discomfort if not well-tolerated and may require surgical removal once their therapeutic function is complete [28].

Figure 3: insoluble ocular insert

table 1. differences between soluble and insoluble ocular inserts

Feature	Soluble Ocular Inserts	Insoluble Ocular Inserts
Material	Made of water-soluble or biodegradable materials (e.g., cellulose, hydrogel)	Made of biocompatible, non-dissolving materials (e.g., silicone, polymer)
Dissolution	Dissolve or degrade over time	Do not dissolve; remain in the eye until removed or worn out
Use Duration	Short-term (typically hours to days) as they dissolve or degrade	Long-term (weeks to months) or permanent (e.g., ocular prosthetics
Applications	Drug delivery (e.g., for dry eye, glaucoma), lubrication	Drug delivery (e.g., long-term glaucoma treatment), ocular prosthetics
Comfort	Generally more comfortable, as they dissolve or disappear	May cause discomfort over time if not well tolerated
Removal	No removal required, as they dissolve or are absorbed	May require surgical or medical removal later
Examples	Lacrisert, dissolving drug inserts	Glaucoma inserts, intraocular implants, ocular prostheses

3.4. Prodrug Approach

Prodrugs are chemically modified compounds designed to improve a drug's pharmacokinetic properties, such as solubility and permeability across the ocular barrier. Once the prodrug reaches its target site, it is metabolized into the active form. This strategy is particularly useful for hydrophobic drugs, enhancing their retention and therapeutic efficacy in the eye [16].

3.5. Gene Therapy for Ocular Diseases

Gene therapy has emerged as a promising approach for the treatment of genetic ocular diseases. Advances in gene delivery technologies, including viral and non-viral vectors, have made it possible to deliver therapeutic genes to the retina, offering the potential for long-term treatment of conditions such as retinitis pigmentosa and Leber's congenital amaurosis.

Lipid Nanoparticles for Gene Delivery: Lipid nanoparticles have shown promise in delivering genes to ocular tissues due to their ability to encapsulate genetic material and protect it from degradation. These nanoparticles can facilitate the efficient transfection of target cells, ensuring that the therapeutic gene is expressed in the retina or other ocular tissues [17].

3.6. Microneedles for Ocular Drug Delivery

Microneedles are a novel delivery system that uses tiny needles to deliver drugs directly to the ocular tissues. This minimally invasive approach is designed to bypass the outer ocular barriers, providing more efficient drug delivery to the posterior segment of the eye [18].

Microneedles for Retinal Diseases: Microneedles can be used to deliver drugs to the retina and vitreous humor for the treatment of retinal diseases, such as diabetic retinopathy and macular degeneration. The use of microneedles offers several advantages over traditional injection methods, including reduced pain, lower risk of infection, and the ability to deliver drugs more precisely to the target tissues [19].

3.7. Ocular Drug Delivery via Contact Lenses

Contact lenses have evolved from being simple vision correction devices to becoming effective platforms for ocular drug delivery. Drug-loaded contact lenses offer continuous drug delivery, addressing both patient compliance and therapeutic efficacy. These lenses are used for administering drugs such as antibiotics, anti-inflammatory agents, and glaucoma medications [20].

3.8. Biodegradable Polymers

Biodegradable polymers have gained popularity in ocular drug delivery due to their ability to provide sustained drug release while eliminating the need for surgical removal after the drug has been delivered. These materials degrade over time, reducing the need for repeated procedures and offering controlled release for the treatment of chronic conditions like glaucoma [22].

4. Challenges and Future Directions:

While significant progress has been made in ocular drug delivery systems, several challenges remain. The complexity of the ocular anatomy, the need for personalized treatment strategies, and the high costs associated with advanced delivery systems are some of the major obstacles to their widespread adoption [29].

4.1. Improving Targeted Delivery:

One of the most significant challenges in ocular drug delivery is achieving precise and targeted drug delivery to specific ocular tissues, such as the retina [33]. Emerging technologies, including targeted nanoparticles, ligand-receptor interactions, and antibody-drug conjugates, offer promising solutions for improving the specificity of ocular drug delivery [31].

4.2. Personalized Medicine:

As ocular drug delivery systems continue to evolve, there is an increasing need for personalized treatment approaches [34]. Genetic profiling and patient-specific drug delivery strategies may help optimize therapeutic outcomes by tailoring treatments to individual patients needs [30].

4.3. Regulatory Challenges:

The development and approval of novel ocular drug delivery systems face significant regulatory challenges [35] .Ensuring the safety, efficacy, and biocompatibility of new drug delivery devices and formulations requires extensive clinical testing and regulatory oversight, which can slow down the process of bringing new treatments to market [32].

5. Conclusion:

Recent advancements in ocular drug delivery systems have brought about promising solutions to the many challenges faced in the treatment of ocular diseases. Nanoparticle-based systems, hydrogels, sustained-release implants, gene therapy, and microneedles represent the cutting edge of ocular drug delivery, offering enhanced drug bioavailability, prolonged release, and targeted therapy. Despite the promising progress, challenges related to drug targeting, patient compliance, and regulatory hurdles still exist. Continued research and innovation in this field hold the potential to transform the treatment of ocular diseases, providing better outcomes and improved quality of life for patients.

6. References:

[1] Ahmed, S., Amin, M. M. & Sayed, S., 2023. Ocular drug delivery: A comprehensive review. *AAPS PharmSciTech*, 24(2), p. 66. DOI: https://doi.org/10.1208/s12249-023-02516-9.

[2] Urtti, A., 2006. Challenges and obstacles of ocular pharmacokinetics and drug delivery. *Advanced Drug Delivery Reviews*, 58(11), pp. 1131–1135. DOI: https://doi.org/10.1016/j.addr.2006.07.027.

[3] Mofidfar, M., Abdi, B., Ahadian, S., Mostafavi, E., Desai, T. A., Abbasi, F., ... & Flowers, C. W., 2021. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. *International Journal of Pharmaceutics*, 607, p. 120924. DOI: https://doi.org/10.1016/j.ijpharm.2021.120924.

[4] Maurice, D. M. & Mishima, S., 1984. Ocular pharmacokinetics. In: *Pharmacology of the Eye*. Berlin, Heidelberg: Springer Berlin Heidelberg, pp. 19-116. DOI: https://doi.org/10.1007/978-3-642-69222-2_2.

[5] Agarwal, R., Iezhitsa, I., Agarwal, P., Abdul Nasir, N. A., Razali, N., Alyautdin, R. & Ismail, N. M., 2016. Liposomes in topical ophthalmic drug delivery: An update. *Drug Delivery*, 23(4), pp. 1075–1091. DOI: https://doi.org/10.3109/10717544.2014.943336.
[6] Prausnitz, M. R. & Noonan, J. S., 1998. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. *Journal of Pharmaceutical Sciences*, 87(12), pp. 1479–1488. DOI: https://doi.org/10.1021/js9802594.
[7] Agrahari, V., Mandal, A., Agrahari, V., Trinh, H. M., Joseph, M., Ray, A., ... & Mitra, A. K., 2016. A comprehensive insight on ocular pharmacokinetics. *Drug Delivery and Translational Research*, 6, pp. 735–754. DOI: https://doi.org/10.1007/s13346-016-0339-2.
[8] Farkouh, A., Frigo, P. & Czejka, M., 2016. Systemic side effects of eye drops: A pharmacokinetic perspective. *Clinical Ophthalmology*, 10, pp. 2433–2441. DOI: https://doi.org/10.2147/OPTH.S118409.

[9] Vaishya, R. D., Khurana, V., Patel, S. & Mitra, A. K., 2014. Controlled ocular drug delivery with nanomicelles. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 6(5), pp. 422–437. DOI: https://doi.org/10.1002/wnan.1272.
[10] Bourzac, K., 2012. Nanotechnology: Carrying drugs. *Nature*, 491(7425), pp. S58–S60. DOI: https://doi.org/10.1038/491s58a.
[11] Tampucci, S., Guazzelli, L., Burgalassi, S., Carpi, S., Chetoni, P., Mezzetta, A., Nieri, P., Polini, B., Pomelli, C. S., Terreni, E. & Monti, D., 2020. pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy. *Pharmaceutics*, 12(11), p. 1078. DOI: https://doi.org/10.3390/pharmaceutics12111078.
[12] Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A. & Kutlu, O., 2020. Therapeutic nanoparticles and their targeted delivery applications. *Molecules (Basel, Switzerland)*, 25(9), p. 2193. DOI: https://doi.org/10.3390/molecules25092193.
[13] Qamar, Z., Qizilbash, F. F., Iqubal, M. K., Ali, A., Narang, J. K., Ali, J. & Baboota, S., 2019. Nano-based drug delivery system: Recent strategies for the treatment of ocular disease and future perspective. *Recent Patents on Drug Delivery & Formulation*, 13(4), pp. 246–254. DOI: https://doi.org/10.2174/1872211314666191224115211.
[14] Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K. & Chourasia, M. K., 2017. Nanoemulsion: Concepts, development and applications in drug delivery. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, 252, pp. 28–49. DOI: https://doi.org/10.1016/j.jconrel.2017.03.008.
[15] Gupta, A., Eral, H. B., Hatton, T. A. & Doyle, P. S., 2016. Nanoemulsions: Formation, properties and applications. *Soft Matter*, 12(11), pp. 2826–2841. DOI: https://doi.org/10.1039/c5sm02958a.
[16] Kale, S. N. & Deore, S. L., 2017. Emulsion microemulsion and nanoemulsion: A review. *Systematic Reviews in Pharmacy*, 8(1), p. 39. DOI: https://doi.org/10.5530/srp.2017.1.8.
[17] Rykowska, I., Nowak, I. & Nowak, R., 2021. Soft contact lenses as drug delivery systems: A review. *Molecules (Basel, Switzerland)*, 26(18), p. 5577. DOI: https://doi.org/10.3390/molecules26185577.
[18] Choi, S. W. & Kim, J., 2018. Therapeutic contact lenses with polymeric vehicles for ocular drug delivery: A review. *Materials (Basel, Switzerland)*, 11(7), p. 1125. DOI: https://doi.org/10.3390/ma11071125.
[19] Irimia, T., Dinu-Pîrvu, C. E., Ghica, M. V., Lupuleasa, D., Muntean, D. L., Udeanu, D. I. & Popa, L., 2018. Chitosan-based in situ gels for ocular delivery of therapeutics: A state-of-the-art review. *Marine Drugs*, 16(10), p. 373. DOI: https://doi.org/10.3390/md16100373.
[20] Fang, G., Wang, Q., Yang, X., Qian, Y., Zhang, G. & Tang, B., 2022. γ-Cyclodextrin-based polypseudorotaxane hydrogels for ophthalmic delivery of flurbiprofen to treat anterior uveitis. *Carbohydrate Polymers*, 277, p. 118889. DOI: https://doi.org/10.1016/j.carbpol.2021.118889.
[21] Musarella, M. A., 1992. Gene mapping of ocular diseases. *Survey of Ophthalmology*, 36(4), pp. 285–312. DOI: https://doi.org/10.1016/0039-6257(92)90096-c.
[22] Tawfik, M., Chen, F., Goldberg, J. L. & Sabel, B. A., 2022. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 395(12), pp. 1477–1507. DOI: https://doi.org/10.1007/s00210-022-02287-3.
[23] Supe, S., Upadhya, A. & Singh, K., 2021. Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review. *Experimental Eye Research*, 202, p. 108329. DOI: https://doi.org/10.1016/j.exer.2020.108329.
[24] Pelusi, L., Mandatori, D., Mastropasqua, L., Agnifili, L., Allegretti, M., Nubile, M. & Pandolfi, A., 2023. Innovation in the development of synthetic and natural ocular drug delivery systems for eye diseases treatment: Focusing on drug-loaded ocular inserts, contacts, and intraocular lenses. *Pharmaceutics*, 15(2), p. 625. DOI: https://doi.org/10.3390/pharmaceutics15020625.
[25] Balguri, S. P., Adelli, G. R., Tatke, A., Janga, K. Y., Bhagav, P. & Majumdar, S., 2017. Melt-cast noninvasive ocular inserts for posterior segment drug delivery. *Journal of Pharmaceutical Sciences*, 106(12), pp. 3515–3523. DOI: https://doi.org/10.1016/j.xphs.2017.07.017.
[26] Kumari, A., Sharma, P. K., Garg, V. K. & Garg, G., 2010. Ocular inserts - Advancement in therapy of eye diseases. *Journal of Advanced Pharmaceutical Technology & Research*, 1(3), pp. 291–296. DOI: https://doi.org/10.4103/0110-5558.72419.
[27] Yang, Y. & Lockwood, A., 2022. Topical ocular drug delivery systems: Innovations for an unmet need. *Experimental Eye Research*, 218, p. 109006. DOI: https://doi.org/10.1016/j.exer.2022.109006.
[28] Shadambikar, G., Marathe, S., Patil, A., Joshi, R., Bandari, S., Majumdar, S. & Repka, M., 2021. Novel application of hot melt extrusion technology for preparation and evaluation of valacyclovir hydrochloride ocular inserts. *AAPS PharmSciTech*, 22(1), p. 48. DOI: https://doi.org/10.1208/s12249-020-01916-5.
[29] Gote, V., Sikder, S., Sicotte, J. & Pal, D., 2019. Ocular drug delivery: Present innovations and future challenges. *The Journal of Pharmacology and Experimental Therapeutics*, 370(3), pp. 602–624. DOI: https://doi.org/10.1124/jpet.119.256933.
[30] Li, S., Chen, L. & Fu, Y., 2023. Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. *Journal of Nanobiotechnology*, 21(1), p. 232. DOI: https://doi.org/10.1186/s12951-023-01992-2.
[31] Regu, V. R., Swain, R. P. & Subudhi, B. B., 2023. Drug delivery for ocular allergy: Current formulation design strategies and future perspectives. *Current Pharmaceutical Design*, 29(33), pp. 2626–2639. DOI: https://doi.org/10.2174/0113816128275375231030115828.

[32] Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M. & Mitra, A. K., 2018. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. *Advanced Drug Delivery Reviews*, 126, pp. 67–95. DOI: https://doi.org/10.1016/j.addr.2018.01.008.

[33] Kim, H. M. & Woo, S. J., 2021. Ocular drug delivery to the retina: Current innovations and future perspectives. *Pharmaceutics*, 13(1), p. 108. DOI: https://doi.org/10.3390/pharmaceutics13010108.

[34] Kaushal, U., Kaur, M., Nagpal, M., Bhuyan, M. & Gounder, K. P., 2023. Nanocarriers based ocular therapeutics: Updates, challenges and future perspectives. *Current Drug Research Reviews*, 15(1), pp. 15–28. DOI: https://doi.org/10.2174/2589977514666220913120718.

[35] Kour, J., Kumari, N. & Sapra, B., 2021. Ocular prodrugs: Attributes and challenges. *Asian Journal of Pharmaceutical Sciences*, 16(2), pp. 175–191. DOI: https://doi.org/10.1016/j.ajps.2020.08.002.